Executive Summary
InMed Pharmaceuticals reported QQ2 2025 results with revenue of USD 1.1117 billion and a gross margin of approximately 41.5%, underscored by substantial operating expenses driven by R&D and G&A. The company posted a net loss of USD 2.575 billion and an EPS of −$3.64 for the quarter, reflecting the ongoing burn typical of early-stage biotechnology pipelines and the timing of milestone-driven costs. Despite the heavy negative bottom-line print, the balance sheet suggests meaningful liquidity with cash and equivalents reported around USD 3.42 billion and modest total debt, implying a potential runway to advance core programs (INM755, INM088, INM405) through pivotal trial milestones and possible collaborations. However, meaningful questions remain around near-term profitability, the cadence of clinical readouts, and the requirement for additional fundraising given the scale of R&D and G&A expenditures.
Key Performance Indicators
Revenue
1.11B
QoQ: 87 807.13% | YoY:89 539.33%
Gross Profit
460.89M
41.46% margin
QoQ: 93 309.38% | YoY:142 088.92%
Operating Income
-2.15B
QoQ: N/A | YoY:-30.52%
Net Income
-2.58B
QoQ: -53.47% | YoY:-174 101.74%
EPS
-3.64
QoQ: -34.32% | YoY:-1 356.00%
Revenue Trend
Margin Analysis
Key Insights
- Revenue: 1,111,707; gross profit: 460,894; gross margin: 41.46%.
- R&D expenses: 1,060,367; G&A expenses: 1,553,583; operating expenses: 2,613,950; EBITDA: -2,099,854; operating income: -2,153,056; operating margin: -193.67%.
- Net income: -2,575,024; net margin: -231.63%; EPS: -3.64; Weighted average shares: 7,065.46k.
- Cash and equivalents: 3,419,422; total current assets: 5,470,120; total current liabilities: 1,790,944; total assets: 8,502,292; total liabilities: 2,320,192; total stockholders’ equity: 6,182,100.
- Net cash provided by operating activities: 1,822,481; free cash flow: -2,502,138; net change in cash: -2,163,617; cash at end of period: 3,419,422. Note: several balance sheet and cash-flow line items appear to reflect unit inconsistencies (USD thousands vs USD millions) in the provided data; investors should treat exact amounts with caution and await supplementary filings for reconciliation.